Subtopic Deep Dive
Plaque Brachytherapy for Choroidal Melanoma
Research Guide
What is Plaque Brachytherapy for Choroidal Melanoma?
Plaque brachytherapy delivers localized radiation using Ruthenium-106 or Iodine-125 plaques to treat medium-sized choroidal melanomas while preserving the eye and vision.
This treatment achieves over 95% local tumor control rates as established by the Collaborative Ocular Melanoma Study (COMS). Key isotopes include Ruthenium-106 for smaller tumors and Iodine-125 for larger ones, with dosimetric guidelines from Simpson et al. (2013). Over 300 citations support its efficacy in eye-sparing therapy (Finger, 1997).
Why It Matters
Plaque brachytherapy serves as the standard for medium-sized choroidal melanomas (2.5-10 mm height, ≤16 mm base), offering 5-year local control >90% per COMS data referenced in Finger (1997). It preserves visual acuity in 50-70% of cases at 5 years, reducing enucleation rates from 100% historically (Simpson et al., 2013). Real-world applications include outpatient procedures minimizing metastasis risk, with staging refinements by Kujala et al. (2013) guiding plaque sizing for 7,369-patient cohorts.
Key Research Challenges
Radiation Retinopathy Management
Radiation retinopathy occurs in 20-50% of cases post-brachytherapy, causing vision loss via vascular occlusion. Management lacks standardized protocols despite COMS insights (Finger, 1997). Simpson et al. (2013) guidelines address dosimetry but not long-term mitigation.
Dosimetric Optimization
Plaque design must match tumor shape for uniform dosing, complicated by ciliary body extension. Ruthenium-106 suits thin tumors but underdoses thicker ones (Simpson et al., 2013). Iodine-125 provides deeper penetration but risks optic neuropathy (Kujala et al., 2013).
Metastasis Prediction
Despite local control, 50% develop liver metastases uncorrelated with local response. Biomarkers like circulating melanoma cells show promise but lack clinical integration (Foss et al., 1995). Damato (2012) highlights surveillance gaps post-treatment.
Essential Papers
Uveal melanoma: relatively rare but deadly cancer
Swathi Kaliki, Carol L. Shields · 2016 · Eye · 624 citations
Uveal melanoma: From diagnosis to treatment and the science in between
Chandrani Chattopadhyay, Dae Won Kim, Dan S. Gombos et al. · 2016 · Cancer · 420 citations
Melanomas of the choroid, ciliary body, and iris of the eye are collectively known as uveal melanomas. These cancers represent 5% of all melanoma diagnoses in the United States, and their age‐adjus...
Uveal melanoma: epidemiology, etiology, and treatment of primary disease
Benjamin A. Krantz, Nikita Dave, Kimberly M. Komatsubara et al. · 2017 · Clinical ophthalmology · 387 citations
Uveal melanoma (UM) is the most common intraocular malignancy and arises from melanocytes in the iris, ciliary body, or choroid. Early diagnosis and local treatment is crucial, as survival correlat...
The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma
E. Rand Simpson, Brenda L. Gallie, Normand Laperrierre et al. · 2013 · Brachytherapy · 328 citations
Radiation therapy for choroidal melanoma
Paul T. Finger · 1997 · Survey of Ophthalmology · 311 citations
Radiotherapy offers patients with malignant melanoma of the choroid an eye and a vision-sparing alternative to enucleation. The most commonly used forms of radiotherapy are ophthalmic plaque brachy...
The biology of uveal melanoma
Adriana Amaro, Rosaria Gangemi, Francesca Piaggio et al. · 2017 · Cancer and Metastasis Reviews · 232 citations
Staging of Ciliary Body and Choroidal Melanomas Based on Anatomic Extent
Emma Kujala, Bertil Damato, Sarah E. Coupland et al. · 2013 · Journal of Clinical Oncology · 174 citations
Purpose To refine the anatomic classification and staging of ciliary body and choroidal melanomas in the TNM classification. Patients and Methods Tumor largest basal diameter and thickness of 7,369...
Reading Guide
Foundational Papers
Start with Simpson et al. (2013, 328 citations) for ABS consensus guidelines on plaque design and dosimetry; Finger (1997, 311 citations) for radiotherapy alternatives to enucleation; Kujala et al. (2013) for TNM staging of 7,369 tumors.
Recent Advances
Krantz et al. (2017, 387 citations) on epidemiology and primary treatment; Kaliki and Shields (2016, 624 citations) on uveal melanoma rarity and deadliness; Chattopadhyay et al. (2016, 420 citations) on diagnosis to treatment pipeline.
Core Methods
Ruthenium-106 plaques for ≤5 mm height (beta-emitter); Iodine-125 for thicker tumors (gamma-emitter, deeper penetration); episcleral placement with COMS dosing (85 Gy apex, Simpson et al., 2013).
How PapersFlow Helps You Research Plaque Brachytherapy for Choroidal Melanoma
Discover & Search
Research Agent uses searchPapers and citationGraph on 'plaque brachytherapy choroidal melanoma' to map 328-citation Simpson et al. (2013) as central node, revealing Finger (1997) connections. exaSearch uncovers COMS dosimetry reports; findSimilarPapers links to Krantz et al. (2017) for medium-tumor protocols.
Analyze & Verify
Analysis Agent applies readPaperContent to extract 95% local control rates from Simpson et al. (2013), then verifyResponse with CoVe checks against Finger (1997). runPythonAnalysis plots retinopathy incidence from 7,369-patient data in Kujala et al. (2013) using pandas; GRADE assigns high evidence to COMS outcomes.
Synthesize & Write
Synthesis Agent detects gaps in retinopathy mitigation via gap detection on Simpson et al. (2013) and Finger (1997). Writing Agent uses latexEditText for dosimetry sections, latexSyncCitations for 300+ refs, and latexCompile for figures; exportMermaid diagrams plaque-tumor dose gradients.
Use Cases
"Analyze retinopathy rates in Ruthenium-106 vs Iodine-125 plaques from COMS data"
Research Agent → searchPapers('COMS plaque brachytherapy') → Analysis Agent → runPythonAnalysis(pandas meta-analysis on rates from Simpson 2013, Finger 1997) → matplotlib survival curves output.
"Draft manuscript section on plaque dosimetry guidelines with citations"
Synthesis Agent → gap detection(Simpson 2013) → Writing Agent → latexEditText(dosimetry text) → latexSyncCitations(328 refs) → latexCompile(PDF with TNM staging table from Kujala 2013).
"Find code for choroidal melanoma plaque simulation models"
Research Agent → paperExtractUrls(Simpson 2013) → paperFindGithubRepo → githubRepoInspect(dosimetry simulators) → runPythonAnalysis(NumPy dose calculator) → validated model output.
Automated Workflows
Deep Research workflow scans 50+ uveal melanoma papers via citationGraph from Simpson et al. (2013), producing GRADE-graded systematic review on local control. DeepScan applies 7-step CoVe to verify 95% efficacy claims against Finger (1997), with Python checkpoint on metastasis data. Theorizer generates hypotheses on isotope selection from Kujala et al. (2013) staging.
Frequently Asked Questions
What is plaque brachytherapy for choroidal melanoma?
It places radioactive plaques (Ruthenium-106 or Iodine-125) on the sclera to deliver 85 Gy apex dose over 3-7 days (Simpson et al., 2013).
What methods define standard plaque brachytherapy?
COMS protocol uses I-125 for medium tumors; ABS guidelines specify plaque design and dosimetry (Simpson et al., 2013; Finger, 1997).
What are key papers on plaque brachytherapy?
Simpson et al. (2013, 328 citations) for guidelines; Finger (1997, 311 citations) for radiation outcomes; Kujala et al. (2013, 174 citations) for staging.
What open problems remain in plaque brachytherapy?
Reducing radiation retinopathy (20-50% incidence) and predicting metastasis despite local control (Foss et al., 1995; Damato, 2012).
Research Ocular Oncology and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Plaque Brachytherapy for Choroidal Melanoma with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Ocular Oncology and Treatments Research Guide